Jeff Cummings

1.5k total citations
27 papers, 1.2k citations indexed

About

Jeff Cummings is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Jeff Cummings has authored 27 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Oncology and 4 papers in Immunology. Recurrent topics in Jeff Cummings's work include Cancer therapeutics and mechanisms (5 papers), Cell death mechanisms and regulation (4 papers) and Bioactive Compounds and Antitumor Agents (3 papers). Jeff Cummings is often cited by papers focused on Cancer therapeutics and mechanisms (5 papers), Cell death mechanisms and regulation (4 papers) and Bioactive Compounds and Antitumor Agents (3 papers). Jeff Cummings collaborates with scholars based in United Kingdom, United States and Sweden. Jeff Cummings's co-authors include Caroline Dive, Malcolm Ranson, Tim Ward, Alastair Greystoke, Duncan I. Jodrell, Timothy H. Ward, Andrew Hughes, Paul Lorigan, Richard L. Hayward and John F. Smyth and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and American Journal Of Pathology.

In The Last Decade

Jeff Cummings

25 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeff Cummings United Kingdom 15 604 512 259 244 133 27 1.2k
Hui Xing China 22 343 0.6× 768 1.5× 387 1.5× 122 0.5× 100 0.8× 54 1.2k
Wilberto Nieves‐Neira United States 17 671 1.1× 1.2k 2.3× 254 1.0× 138 0.6× 138 1.0× 29 1.7k
Radosław Januchowski Poland 24 736 1.2× 1.1k 2.1× 476 1.8× 224 0.9× 125 0.9× 53 1.8k
Danhui Weng China 22 492 0.8× 926 1.8× 471 1.8× 160 0.7× 79 0.6× 41 1.5k
Milena Casula Italy 23 733 1.2× 864 1.7× 302 1.2× 275 1.1× 328 2.5× 52 1.5k
Karen S. Flatten United States 24 814 1.3× 1.4k 2.8× 226 0.9× 167 0.7× 102 0.8× 45 1.9k
Bridget A. Quinn United States 16 408 0.7× 454 0.9× 110 0.4× 168 0.7× 44 0.3× 24 965
Maria Cristina Sini Italy 22 710 1.2× 1.0k 2.0× 445 1.7× 205 0.8× 188 1.4× 59 1.5k
Loredana Cleris Italy 27 543 0.9× 1.5k 2.9× 325 1.3× 258 1.1× 227 1.7× 54 2.5k
Sachiko Ogasawara Japan 22 519 0.9× 740 1.4× 406 1.6× 211 0.9× 163 1.2× 78 1.6k

Countries citing papers authored by Jeff Cummings

Since Specialization
Citations

This map shows the geographic impact of Jeff Cummings's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeff Cummings with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeff Cummings more than expected).

Fields of papers citing papers by Jeff Cummings

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeff Cummings. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeff Cummings. The network helps show where Jeff Cummings may publish in the future.

Co-authorship network of co-authors of Jeff Cummings

This figure shows the co-authorship network connecting the top 25 collaborators of Jeff Cummings. A scholar is included among the top collaborators of Jeff Cummings based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeff Cummings. Jeff Cummings is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cummings, Jeff, Kevin Matthews, & Thomas Janicki. (2025). Invited Paper Survey of Technology and Skills in Demand: The 2024 Update. Journal of the Association for Information Systems. 35(2). 195–208. 1 indexed citations
2.
Cummings, Jeff & Thomas Janicki. (2021). Invited Report : Survey of Technology and Skills in Demand: 2020 Update.. 32. 150–159. 1 indexed citations
3.
Khoja, Leila, Paul Lorigan, Cong Zhou, et al.. (2012). Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma. Journal of Investigative Dermatology. 133(6). 1582–1590. 107 indexed citations
4.
Cummings, Jeff, Martin Zweifel, Nicola L. Smith, et al.. (2012). Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial. British Journal of Cancer. 106(11). 1766–1771. 23 indexed citations
5.
Coward, Jermaine, Hagen Kulbe, Probir Chakravarty, et al.. (2011). Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer. Clinical Cancer Research. 17(18). 6083–6096. 313 indexed citations
6.
Danson, Sarah, Peter Johnson, Tim Ward, et al.. (2011). Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1. Annals of Oncology. 22(7). 1653–1660. 26 indexed citations
7.
Brookes, Keeley J., Jeff Cummings, Alison Backen, et al.. (2010). Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs. British Journal of Cancer. 102(10). 1524–1532. 12 indexed citations
8.
Hampson, Grace, Tim Ward, Jeff Cummings, et al.. (2010). Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects. Journal of Immunological Methods. 360(1-2). 30–38. 25 indexed citations
9.
10.
Hou, Jianmei, Alastair Greystoke, Lee Lancashire, et al.. (2009). Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy. American Journal Of Pathology. 175(2). 808–816. 189 indexed citations
11.
Ranson, Malcolm, Emma Dean, Tim Ward, et al.. (2007). Cell death ELISAs in the phase I clinical evaluation of AEG35156 (XIAP antisense) administered as an intravenous infusion over 7-days, 3-days, and 2-hours.. Molecular Cancer Therapeutics. 6.
12.
Cummings, Jeff, Timothy H. Ward, Alastair Greystoke, Malcolm Ranson, & Caroline Dive. (2007). Biomarker method validation in anticancer drug development. British Journal of Pharmacology. 153(4). 646–656. 97 indexed citations
13.
Greystoke, Alastair, Andrew Hughes, Malcolm Ranson, et al.. (2007). Serum biomarkers of apoptosis. European Journal of Cancer Supplements. 5(5). 115–127. 3 indexed citations
14.
Cummings, Jeff, Tim Ward, Malcolm Ranson, & Caroline Dive. (2004). Apoptosis pathway-targeted drugs—from the bench to the clinic. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1705(1). 53–66. 65 indexed citations
15.
Hayward, Richard L., Janet S. Macpherson, Jeff Cummings, et al.. (2003). Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.. PubMed. 9(7). 2856–65. 56 indexed citations
16.
Jodrell, Duncan I., Marlene Stewart, Rhona Aird, et al.. (2001). 5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer. British Journal of Cancer. 84(5). 600–603. 28 indexed citations
17.
Cummings, Jeff, et al.. (1998). Pharmacological determinants of the antitumour activity of mitomycin C - implications for enzyme directed drug development. UCL Discovery (University College London). 2 indexed citations
18.
19.
Newton, J.M., et al.. (1995). Amylose, the new perspective in oral drug delivery to the human large intestine. CentAUR (University of Reading). 5(1). 47–53. 36 indexed citations
20.
Newton, J.M., Jeff Cummings, Glenn Gibson, et al.. (1993). In vitro and in vivo evaluation of amylose coated pellets for colon specific drug delivery. CentAUR (University of Reading). 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hui Xing Breakdown of academic impact, for papers by Wilberto Nieves‐Neira Breakdown of academic impact, for papers by Radosław Januchowski Breakdown of academic impact, for papers by Danhui Weng Breakdown of academic impact, for papers by Milena Casula Breakdown of academic impact, for papers by Karen S. Flatten Breakdown of academic impact, for papers by Bridget A. Quinn Breakdown of academic impact, for papers by Maria Cristina Sini Breakdown of academic impact, for papers by Loredana Cleris Breakdown of academic impact, for papers by Sachiko Ogasawara
Rankless by CCL
2026